MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

SOX9

  • Home
  • SOX9
Targeting SOX9-Driven SPEM Plasticity: A New Therapeutic Avenue to Prevent Gastric Cancer Progression
Posted inGastroenterology news Oncology

Targeting SOX9-Driven SPEM Plasticity: A New Therapeutic Avenue to Prevent Gastric Cancer Progression

Posted by By MedXY 07/16/2026
SOX9 is a pivotal regulator of SPEM cell plasticity driving gastric metaplasia and carcinogenesis. Therapeutically targeting SOX9 may prevent the progression of pre-cancerous lesions to gastric cancer by blocking metaplastic evolution.
Read More
Therapeutic Reversal of SOX9-Mediated Chemoresistance in Esophageal Adenocarcinoma via APE1-Redox Inhibition
Posted inClinical Updates news Oncology

Therapeutic Reversal of SOX9-Mediated Chemoresistance in Esophageal Adenocarcinoma via APE1-Redox Inhibition

Posted by By MedXY 03/15/2026
This review details a breakthrough in esophageal adenocarcinoma treatment, identifying the APE1-SOX9 axis as a primary driver of chemoresistance and demonstrating how targeting APE1's redox function can sensitize tumors to oxaliplatin.
Read More
  • Evolving Critical Care Needs and Outcomes in Andes Virus-Associated Hantavirus Cardiopulmonary Syndrome: Insights from a National Chilean Cohort
  • Rapid Immunoassay for Molecular Subphenotyping in Pediatric Acute Cardiorespiratory Failure: Clinical Implications and Future Directions
  • Childhood Mental Health-Related Emergency Department Visits and Pediatric Volume Dynamics in the US (2016-2022): A Comprehensive Review
  • Unveiling the Impact of Social Determinants of Health Screening: Insights from an 18-Hospital Network Implementation
  • Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women with Vasomotor Symptoms: Insights from the SWAN Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top